A Stock Recent News

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on July 23, 2025, to all shareholders of record as of the close of business on July 1, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Pascal Soriot, CEO of AstraZeneca, and Judy Gawlik Brown, founder and CEO of Downtown Advisory, have been elected to its Board of Directors, effective May 21, 2025. Soriot and Gawlik Brown bring decades of global leadership experience across the pharmaceutical, biotechnology, and health-care sectors, with proven track records in strategy, innovation, operations, and finance. Pascal Soriot has led Astr.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Infinity III LC Series — the company's latest liquid chromatography (LC) instruments — are the first Agilent instruments to receive the new My Green Lab® ACT® Ecolabel 2.0, further reinforcing Agilent's commitment to sustainable scientific innovation. Designed for efficiency, upgradeability, and environmental responsibility, the Infinity III LC Series offers laboratories a forward-thinking approac.

SANTA CLARA, Calif--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell — along with CFO Bob McMahon — will participate in a fireside chat at the Jefferies Global Healthcare Conference at 10:30 a.m. Eastern on Wednesday, June 4, 2025, in New York City. A live audio webcast and replay of the presentation will be available on the Agilent Investor Relations website. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in anal.

Scale is a critical competitive advantage for companies, enabling them to expand, attract capital, and achieve strong market positions, as seen with Realty Income, Prologis, and Public Storage. Realty Income leverages its scale and diversification to maintain high occupancy rates and strong financial performance, boasting a fortress balance sheet and impressive dividend growth. Prologis excels with its vast warehouse portfolio, robust development pipeline, and strategic expansion into data centers, supported by a strong balance sheet and high earnings growth.

Agilent (A) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

This month's preferred stock IPO market is frozen, dominated by “Par Cross” and “Insider Buying” alerts, reflecting investor uncertainty due to trade tensions. The trade war and tariffs have created significant market volatility, causing companies to withdraw earnings guidance and defer investment decisions. Preferred stocks and baby bonds offer fixed payments, making them attractive during uncertain times, as they provide a “known return” amidst market unpredictability.

City Office REIT's Series A Preferred Shares offer a tempting yield despite recent accounting losses and systemic pressures, suggesting a potential buying opportunity. The shares are cumulative, redeemable, and fixed, ensuring eventual dividend payments, though call risk and financial restructuring are potential concerns. The REIT's fundamentals, including an 85.8% occupancy rate and sector diversification, support sustainability, with positive economic profitability and AFFO figures.

LEWISVILLE, Ark., April 24, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture (“JV”) between Standard Lithium Ltd.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions t.